Niocorp Developments

After touching a 52-week low of $2.59 on Nov 5, NB slipped to $2.650 in Thursday's pre-market but reversed to close the regular session at $2.895, up 7.02%, with an intraday high of $2.910 and a slight fade to $2.890 after hours; the rebound was set off by a 15-year offtake agreement with Traxys covering Elk Creek products, which places all planned critical-mineral output under long-term sales contracts, alongside EXIM reiterating its target to finance roughly 65% of upfront CAPEX. Q3 2026 net income of $0.878M turned positive year over year, but the Q4 operating loss widened to $9.459M and the net loss reached $5.954M. The shares remain below the MA20 of 3.133 and MA60 of 3.65, down 51.34% year to date and 64.61% below the 52-week high of $8.18, while William Blair's challenge to rare-earth supply optimism still weighs on the group and a 1.56% turnover rate points to thin participation.

An 8-K showing zero quarterly revenue, plus broad weakness in materials names, left NB down 8.9% at $2.705, after spiking to $3.130 pre-market and then sliding to a $2.595 intraday low, a fresh 52-week low, before a partial recovery into the close. The project story is not empty: 100% of planned Elk Creek output is contracted under long-term sales agreements, including a 15-year supply deal with Traxys, EXIM reiterated financing of roughly 65% of upfront CAPEX, and preliminary Q3 results showed $8.78 million of net income, up 116.7% year over year. Still, the price sits below its MA20 of $3.157 and MA60 of $3.687, down 54.54% year to date and 66.93% below the January 26 high of $8.18, at 0.91x book with a market value of about $395 million, and post-market trades near $2.700. Though the latest quarter's operating loss widened 86.83% to $9.459 million, keeping pre-construction spending pressure visible.

NioCorp rose in premarket but faded to close essentially flat on Nov. 4, with the latest $2.97 down 0.3% from the $2.98 prior close, as the market digested the prior 15% rebound and Elk Creek commercial updates. The stock hit $3.20 premarket, touched $3.175 at 09:41 ET, fell to $2.873 by 11:05 ET, recovered to $2.975, and last traded at $2.97 after hours. NioCorp has placed 100% of planned Elk Creek output under long-term sales agreements, including a 15-year Traxys supply deal, while EXIM reiterated a target to finance about 65% of upfront capex. Those items supported the premarket move but did not hold. Recent results show Q3 net income of $0.878 million and EPS of $0.0066, versus a Q4 net loss of $5.954 million and an operating loss of $9.459 million, highlighting development-stage spending. At $2.97, the shares sit 63.69% below the 52-week high of $8.18, down 50.08% year-to-date, below the MA20 of $3.192 and MA60 of $3.729, and just 5.69% above the 52-week low of $2.81. Though the long-term sales coverage anchors project financing, the stock remains below both moving averages.

Shares spiked to $3.25 pre-market before sliding one-way through the regular session to a $2.954 low and closing at $2.99 against a $3.115 prior close, about 4% lower, as the late-October 15% single-day rally unwound. Project news flow has been steady: all planned Elk Creek output is now covered by long-term sales agreements, including a 15-year supply contract with Traxys, and EXIM reiterated it aims to finance roughly 65% of upfront capex; yet the 8-K shows zero revenue for FY2027 Q1, while Q4 2026 recorded a $5.954M net loss and a $9.459M operating loss. The stock is down 49.92% year to date, 63.57% below its January 26 high of $8.18 and only 6.05% above its 52-week low of $2.81, trading beneath both the $3.216 MA20 and $3.769 MA60 at 1.01x book. Turnover of just 1.51% suggests selling was not broad-based.

NioCorp rose 17.6% to $3.41, staging a low-open, high-close session from $2.98 after touching $2.861 pre-market, closing the regular session at $3.425 and extending to $3.44 after hours, as the company said 100% of planned Elk Creek output is now under long-term sales agreements, including a 15-year supply deal with Traxys, while EXIM reiterated a target to finance roughly 65% of upfront capex. Fundamentals remain pre-revenue: revenue was zero in the latest quarter, with a Q4 net loss of $5.954M, an operating loss of $9.459M and EPS of -$0.0409. The stock is still down 42.69% YTD and 58.31% below its January 52-week high of $8.18, just above the $3.265 MA20 but well under the $3.929 MA60, and 21.35% above the Oct 26 low of $2.81, with market cap near $497M and PB at 1.15. Though the offtake and financing still await final execution, and with no revenue, earnings hinge on construction progress.